Effect of Amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function.
Article
in English
| IMSEAR
| ID: sea-44882
ABSTRACT
BACKGROUND:
Amifostine has a potential role for salivary gland protection in head and neck cancer patients who had radiotherapy. MATERIAL ANDMETHOD:
Sixty-seven head and neck cancer patients were randomized to receive radiotherapy or radiotherapy plus Amifostine. The efficacy of the treatment was determined by a questionnaire evaluating dryness of mouth and the oral comfort, the RTOG/EORTC acute/late radiation morbidity scoring criteria, collection of the whole saliva and the 99mTc-pertecnetate scintigraphy of the salivary glands.RESULTS:
Amifostine significantly reduced the mean questionnaire scores from 6.49 to 3.73, the incidence of grade > or = 2 mucositis from 75% to 36% and acute xerostomia from 82% to 39%. The salivary gland function returned to normal at a rate of 36.3% in the Amifostine group versus 9.1% in the control group.CONCLUSION:
Amifostine is effective in reducing the incidence and severity of acute mucositis, acute and late xerostomia in head and neck cancer patients.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Radiation Injuries
/
Radiation-Protective Agents
/
Salivary Glands
/
Aged
/
Female
/
Humans
/
Male
/
Carcinoma, Squamous Cell
/
Chi-Square Distribution
/
Amifostine
Type of study:
Controlled clinical trial
Language:
English
Year:
2006
Type:
Article
Similar
MEDLINE
...
LILACS
LIS